Lynozyfic
Payments companies reported to CMS as associated with Lynozyfic. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Lynozyfic, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Lynozyfic
These are the largest totals companies reported as associated with Lynozyfic. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Habte Yimer | Tyler, TX | Hematology & Oncology | $41,220.67 |
| Irene Ghobrial | Boston, MA | Medical Oncology | $29,208.60 |
| Rafael Fonseca | Scottsdale, AZ | Hematology (Internal Medicine) | $27,861.04 |
| Hakan Kaya | Spokane, WA | Medical Oncology | $24,380.40 |
| Moshe Levy | Dallas, TX | Medical Oncology | $23,151.81 |
| Luciano Costa | Birmingham, AL | Hematology & Oncology | $22,443.11 |
| Dickran Kazandjian | Miami, FL | Hematology & Oncology | $21,252.02 |
| Ivan Borrello | Tampa, FL | Medical Oncology | $20,752.70 |
| Mansi Shah | New Brunswick, NJ | Hematology (Internal Medicine) | $16,033.04 |
| Chakra Chaulagain | Weston, FL | Hematology & Oncology | $14,801.25 |
Prescribed Lynozyfic?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.